[go: up one dir, main page]

ES2182867T3 - Anticuerpo monoclonal contra el factor citotoxico tumoral ii (tcf-ii). - Google Patents

Anticuerpo monoclonal contra el factor citotoxico tumoral ii (tcf-ii).

Info

Publication number
ES2182867T3
ES2182867T3 ES95301800T ES95301800T ES2182867T3 ES 2182867 T3 ES2182867 T3 ES 2182867T3 ES 95301800 T ES95301800 T ES 95301800T ES 95301800 T ES95301800 T ES 95301800T ES 2182867 T3 ES2182867 T3 ES 2182867T3
Authority
ES
Spain
Prior art keywords
tcf
monoclonal antibody
antibody against
against tumor
cytotoxic factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95301800T
Other languages
English (en)
Inventor
Kanji Higashio
Nobuyuki Shima
Fumiko Oogaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2182867T3 publication Critical patent/ES2182867T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A UN ANTICUERPO MONOCLONAL QUE TIENE AFINIDAD AL TCF-II HUMANO SIN NINGUNA AFINIDAD AL HGF Y METODO DE DETERMINACION Y PURIFICACION DEL TCF-II QUE UTILIZA EL ANTICUERPO. EL ANTICUERPO MONOCLONAL SE PUEDE OBTENER MEDIANTE LA ADICION DE UNA SOLUCION DE BLOQUEO QUE CONTIENE UN AGENTE ACTIVO DE SUPERFICIE EN EL MEDIO DE CULTIVO QUE CONTIENE EL ANTICUERPO MONOCLONAL PARA BLOQUEAR ANTICUERPOS DIFERENTES DE DICHO ANTICUERPO MONOCLONAL, SEGUIDO POR UNA REACCION CON UN ANTIGENO DE FASE SOLIDA, TCF-II. EL TCF-II HUMANO PUEDE SER SELECTIVA Y EFECTIVAMENTE PURIFICADO O DETERMINADO SIN NINGUNA INFLUENCIA DE LA PRESENCIA DE HGF MEDIANTE LA UTILIZACION DEL ANTICUERPO.
ES95301800T 1994-03-18 1995-03-17 Anticuerpo monoclonal contra el factor citotoxico tumoral ii (tcf-ii). Expired - Lifetime ES2182867T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6074263A JPH07258298A (ja) 1994-03-18 1994-03-18 モノクローナル抗体

Publications (1)

Publication Number Publication Date
ES2182867T3 true ES2182867T3 (es) 2003-03-16

Family

ID=13542077

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95301800T Expired - Lifetime ES2182867T3 (es) 1994-03-18 1995-03-17 Anticuerpo monoclonal contra el factor citotoxico tumoral ii (tcf-ii).

Country Status (11)

Country Link
US (1) US5658742A (es)
EP (1) EP0672685B1 (es)
JP (1) JPH07258298A (es)
AT (1) ATE222927T1 (es)
AU (1) AU684132B2 (es)
CA (1) CA2145005C (es)
DE (1) DE69527868T2 (es)
DK (1) DK0672685T3 (es)
ES (1) ES2182867T3 (es)
NZ (1) NZ270743A (es)
ZA (1) ZA952125B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821223A (en) * 1990-09-14 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating cell growth with a novel broad spectrum human lung fibroblast-derived mitogen
JP4006058B2 (ja) * 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び／又は治療剤
DE69836315T2 (de) * 1997-03-14 2007-05-31 Daiichi Pharmaceutical Co., Ltd. Verwendung von TCF-II zur Behandlung von durch Krebs verursachtem Gewichtsverlust, Anaemie und TNF-Erhöhung
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
JP2003047470A (ja) * 2001-08-01 2003-02-18 Asahi Kasei Corp 新規な抗体及びその用途
US8575099B2 (en) * 2006-04-20 2013-11-05 Osaka University Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0597A (ja) * 1991-06-21 1993-01-08 Snow Brand Milk Prod Co Ltd 新規抗ｔｃｆ−ｉｉモノクローナル抗体及びそれを用いるｔｃｆ−ｉｉの測定方法

Also Published As

Publication number Publication date
AU1493995A (en) 1995-09-28
CA2145005C (en) 2005-06-21
DE69527868T2 (de) 2003-05-08
CA2145005A1 (en) 1995-09-19
JPH07258298A (ja) 1995-10-09
AU684132B2 (en) 1997-12-04
EP0672685A3 (en) 1997-01-15
ZA952125B (en) 1995-12-14
EP0672685A2 (en) 1995-09-20
EP0672685B1 (en) 2002-08-28
DK0672685T3 (da) 2003-01-06
US5658742A (en) 1997-08-19
NZ270743A (en) 1996-06-25
DE69527868D1 (de) 2002-10-02
ATE222927T1 (de) 2002-09-15

Similar Documents

Publication Publication Date Title
ATE208820T1 (de) Humanisierte antikoerper
ATE218387T1 (de) Antikörperreinigung
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
DE69233104D1 (de) Herstellung von Antikörpern
NO965239L (no) Monoklonalt antistoff mot CD44v6
DK388384D0 (da) Monoklone antistoffer med specifitet for membran-associerede antigene, deres fremstilling og anvendelse
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
ES2182867T3 (es) Anticuerpo monoclonal contra el factor citotoxico tumoral ii (tcf-ii).
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
ATE490271T1 (de) Rezeptor, dessen verwendung sowie mausantikörper
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
DE3579808D1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
Moţa et al. In vivo follow-up of the cytotoxic effect of protein A—ricin toxin conjugate, on antibody-coated target cells
IT8421612A0 (it) Vettore clonante, procedimento per la sua costruzione e procedimentodi concentrazione e di purificazione di proteine prodotte, formate dal vettore clonante.